Synlogic 

$0.7010
16
-$0.01-1.51% Wednesday 14:12

Statistics

Day High
0.701
Day Low
0.701
52W High
1.96
52W Low
0.54
Volume
2,100
Avg. Volume
11,639
Mkt Cap
8.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.18
-0.12
-0.07
-0.01
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-1.01MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYBX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic medicine space similar to Synlogic's approach to synthetic biotics.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the field of genetic and cellular therapies where Synlogic operates.
Editas Medicine
EDIT
Mkt Cap560.14M
Editas Medicine works on gene editing using CRISPR technology, directly competing with Synlogic in the development of novel genetic treatments.
Intellia Therapeutics
NTLA
Mkt Cap2.45B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, making it a competitor in the genetic therapy market.
Beam Therapeutics
BEAM
Mkt Cap3.58B
Beam Therapeutics focuses on precision genetic medicines using base editing, a next-generation CRISPR technology, competing in the same innovative healthcare sector.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and gene regulation, positioning it as a competitor in the genetic treatment market.
Regenxbio
RGNX
Mkt Cap686.54M
REGENXBIO is a leader in the development of AAV-based gene therapies, which places it in competition with companies developing other advanced genetic therapies.
Fate Therapeutics
FATE
Mkt Cap340.35M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the cell therapy space alongside Synlogic's synthetic biotics approach.

About

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Show more...
CEO
Ms. Mary Beth Dooley
Employees
1
Country
United States
ISIN
US87166L2097

Listings

0 Comments

Share your thoughts

FAQ

What is Synlogic stock price today?
The current price of SYBX is $0.70 USD — it has decreased by -1.51% in the past 24 hours. Watch Synlogic stock price performance more closely on the chart.
What is Synlogic stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Synlogic stocks are traded under the ticker SYBX.
Is Synlogic stock price growing?
SYBX stock has risen by +0% compared to the previous week, the month change is a +6.21% rise, over the last year Synlogic has showed a -43.47% decrease.
What is Synlogic market cap?
Today Synlogic has the market capitalization of 8.2M
When is the next Synlogic earnings date?
Synlogic is going to release the next earnings report on August 06, 2026.
What is Synlogic revenue for the last year?
Synlogic revenue for the last year amounts to 0 USD.
What is Synlogic net income for the last year?
SYBX net income for the last year is -1.01M USD.
How many employees does Synlogic have?
As of July 09, 2026, the company has 1 employees.
In which sector is Synlogic located?
Synlogic operates in the Health & Wellness sector.
When did Synlogic complete a stock split?
The last stock split for Synlogic was on September 28, 2023 with a ratio of 1:15.
Where is Synlogic headquartered?
Synlogic is headquartered in Winchester, United States.